Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck KGaA
Biotech
Regeneron, Sanofi receive 1- to 2-month priority review vouchers
The national priority vouchers position companies including Merck KGaA, Regeneron and Sanofi to complete the review process in one to two months.
Nick Paul Taylor
Oct 17, 2025 8:30am
As 2 CEOs depart, life sciences face leadership void for women
Oct 3, 2025 11:22am
Merck KGaA picks new pilot for turbulent times—Chutes & Ladders
Sep 26, 2025 8:30am
Merck KGaA lands new R&D chief—Chutes & Ladders
Sep 5, 2025 8:30am
Merck KGaA swoops to $2B neurological disease pact with Skyhawk
Aug 18, 2025 9:49am
Merck KGaA sheds light on failed portion of phase 2 lupus trial
Jun 12, 2025 9:41am
